Literature DB >> 31537990

Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism.

Mark B Zimering1,2, Shree G Nadkarni1.   

Abstract

AIMS: To test whether neurite-inhibitory plasma autoantibodies in chronic schizophrenia activate Gq/11- and Gi- coupled signaling pathways downstream of 5-hydroxytryptamine 2A receptor activation; and for modulation of serotonergic signaling by the metabotropic 2/3 receptor agonist LY379268.
METHODS: Plasma from five older adults with chronic schizophrenia and eight age-matched patients having another neuropsychiatric, immune or metabolic disorder was subjected to Protein-A affinity chromatography to obtain IgG autoantibodies. Mean neurite retraction (5 minutes) or cell survival (24 hours) was determined in mouse N2A neuroblastoma cells incubated with autoantibodies in the presence or absence of specific antagonists of the Gq/11/PLC/IP3R signaling pathway, Gi-coupled, beta-arrestin2-directed pathways, or LY379268.
RESULTS: Chronic schizophrenia plasma autoantibodies- mediated dose- and time-dependent acute N2A neurite retraction was completely prevented by M100907, a selective 5-hydroxytryptamine 2A receptor antagonist. LY379268 promoted autoantibody-induced neurite retraction causing a shift-to-the-left in the dose-response curve. Antagonists of the RhoA/Rho kinase and Gq/11/PLC/IP3R signaling pathways blocked autoantibody-mediated neurite retraction. Chronic schizophrenia plasma autoantibodies mediated increased N2A cell survival which was blocked by LY379268, pertussis toxin, and antagonists of PI3-kinase- mediated survival signaling.
CONCLUSION: Schizophrenia plasma autoantibodies activate the 5-hydroxytryptamine 2A receptor positively coupled to Gq/11/PLC/IP3R pathway and RhoA/Rho kinase signaling activation in promoting acute N2A cell neurite retraction. Autoantibodies in a subset of patients experiencing hallucinations promoted increased N2A cell survival mediated (in part) via a pertussis-toxin sensitive, Gi-coupled, PI3-kinase-dependent mechanism. Positive modulation of 5-HT2AR-mediated neurite retraction by LY379268 suggests the autoantibodies may target (in part) the 5-HT2AR/mGlu2R heteromer.

Entities:  

Year:  2019        PMID: 31537990      PMCID: PMC6751558     

Source DB:  PubMed          Journal:  Endocrinol Diabetes Metab J        ISSN: 2002-7354


  25 in total

1.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

Review 2.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

3.  Crystal Structure of an LSD-Bound Human Serotonin Receptor.

Authors:  Daniel Wacker; Sheng Wang; John D McCorvy; Robin M Betz; A J Venkatakrishnan; Anat Levit; Katherine Lansu; Zachary L Schools; Tao Che; David E Nichols; Brian K Shoichet; Ron O Dror; Bryan L Roth
Journal:  Cell       Date:  2017-01-26       Impact factor: 41.582

4.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

5.  Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.

Authors:  J I Johnsen; L Segerström; A Orrego; L Elfman; M Henriksson; B Kågedal; S Eksborg; B Sveinbjörnsson; P Kogner
Journal:  Oncogene       Date:  2007-11-19       Impact factor: 9.867

6.  Constitutively active Gq/11-coupled receptors enable signaling by co-expressed G(i/o)-coupled receptors.

Authors:  Remko A Bakker; Paola Casarosa; Henk Timmerman; Martine J Smit; Rob Leurs
Journal:  J Biol Chem       Date:  2003-11-10       Impact factor: 5.157

7.  The 5-HT(2A) Receptor Antagonist M100907 Produces Antiparkinsonian Effects and Decreases Striatal Glutamate.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar
Journal:  Front Syst Neurosci       Date:  2011-06-14

8.  Circulating Neurotoxic 5-HT2A Receptor Agonist Autoantibodies in Adult Type 2 Diabetes with Parkinson's Disease.

Authors:  Mark B Zimering
Journal:  J Endocrinol Diabetes       Date:  2018-05-10

9.  Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway.

Authors:  Mark B Zimering
Journal:  J Endocrinol Diabetes       Date:  2017-10-04

Review 10.  Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.

Authors:  Carolina Muguruza; J Javier Meana; Luis F Callado
Journal:  Front Pharmacol       Date:  2016-05-20       Impact factor: 5.810

View more
  3 in total

1.  Severe COVID-19 Pneumonia is Associated with Increased Plasma Immunoglobulin G Agonist Autoantibodies Targeting the 5-Hydroxytryptamine 2A Receptor.

Authors:  Mark B Zimering
Journal:  Endocrinol Diabetes Metab J       Date:  2021-02-02

2.  Circulating Agonist Autoantibody to 5-Hydroxytryptamine 2A Receptor in Lean and Diabetic Fatty Zucker Rat Strains.

Authors:  M B Zimering; M Grinberg; J Burton; Kch Pang
Journal:  Endocrinol Diabetes Metab J       Date:  2020-08-28

3.  Autoantibodies and Cardiomyopathy: Focus on Beta-1 Adrenergic Receptor Autoantibodies.

Authors:  Wai Hong Wilson Tang; Sathyamangla V Naga Prasad
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.